Has Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) Found the Fountain of Youth?



We just recently mentioned Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) which is, among other things, proprietor of a patented process known CaverStem™ for the treatment of erectile dysfunction, a problem affecting tens of millions of men around the globe, and perhaps more, to varying levels of severity.

We felt the need to come back to CELZ so soon because of the big news from the company to hit the wires, concerning an exciting step for another of the company’s stem cell products we’ve mentioned before, known as AmnioStem™.

Creative Medical Technology Holdings, Inc. (OTCMKTS:CELZ) filing of patent application number 62663912 covering the use of AmnioStemTM stem cells as a means of reducing/reversing natural aging. Previous studies by the Company have demonstrated that AmnioStemTM cells secrete factors that are capable of rejuvenating aged cells.  By encapsulating the cells outside of the body, so that the cells are in contact with the patient’s circulation, the cells are permitted to secrete factors that may reduce aging, without having to inject the cells in the patient.

The concept of using cells that are growing outside of the body as a means of modifying physiological activities has previously been performed and appears feasible.  Specifically, similar approaches to mixing patient blood with cells outside of the body have previously been attempted in the area of liver failure.  A clinical trial demonstrated feasibility of using cell culture of hepatocytes to act as a “liver assist device”.  These devices are currently in Phase 3 of clinical trials.

The filed patent describes a similar approach to those used in liver failure, with the exception that instead of using hepatocytes outside of the body, the device uses AmnioStemTM amniotic fluid derived stem cells.

“Previous studies from Stanford University and Harvard University have shown that if the circulation of an aged mouse is connected to the circulation of a young mouse, various factors secreted by young mice induce an anti-aging/rejuvenating effects on organs/tissues of aged mice.  Through this patent, we are aiming to recapitulate this effect, in an ethical and technically feasible manner.” Said Dr. Thomas Ichim, the Company’s Chief Scientific Officer. “What is stunning about the AmnioStemTM stem cell, which was licensed by the Company from the University of California San Diego, is that it possesses many regenerative features but is collected from non-controversial sources.”

The AmnioStemTM stem cell is derived from amniotic fluid during the process of amniocentesis.  Amniotic fluid is typically considered medical waste.  Scientists at University of California San Diego have developed means of extracting and growing stem cells from the amniotic fluid.  These stem cells have been published to be capable of treating animal models of numerous diseases including stroke, heart attack, liver failure, colitis, diabetes, emphysema, and kidney injury.  An important activity of amniotic fluid stem cells is that cells derived from one person can be used to treat other people, making them “universal donor” stem cells.

“At Creative Medical Technology Holdings we are committed to advancing regenerative medicine to various areas of human suffering.  In contrast to other conditions, aging will occur in everyone,” said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. “While the field of anti-aging medicine is filled with various false hopes and hype, we are attempting to address this problem cautiously and methodologically through testing our technology for safety and efficacy. Our goal is to continue to internally develop and patent technology in the regenerative medicine space and to broaden our patent portfolio for future commercialization by the company and/or with other life science companies with complementary technology.” (Source: PR Newswire)

Has CELZ found the fountain of youth? Perhaps not, but if the potential demonstrated in its studies were significant enough to warrant this patent application, we have to be interested in following the story closely from here on out. We’ll stay up on any further developments with CELZ and pass them along to you! Stay locked on StreetRegister.com and be sure you’re signed up for our 100% free smallcap newsletter. It’s as easy as that! Simply submit your primary active email address in the box below. Subscribe now!

Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in CELZ stock, short or long.